Edwards Lifesciences (NYSE:EW) Issues FY 2026 Earnings Guidance

Edwards Lifesciences (NYSE:EW) issued an update on its FY 2026 earnings guidance on Thursday morning. The company provided earnings per share guidance of 2.800-2.950 for the period, compared to the consensus earnings per share estimate of 2.860. The company issued revenue guidance of $6.4 billion-$6.8 billion, compared to the consensus revenue estimate of $6.6 billion.

Edwards Lifesciences Stock Up 2.1%

Shares of NYSE EW opened at $85.72 on Friday. The stock has a market capitalization of $49.74 billion, a price-to-earnings ratio of 36.95, a price-to-earnings-growth ratio of 3.72 and a beta of 0.97. Edwards Lifesciences has a 52 week low of $65.94 and a 52 week high of $87.40. The firm has a 50-day moving average price of $80.75 and a 200 day moving average price of $78.68. The company has a quick ratio of 3.29, a current ratio of 4.00 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Thursday, October 30th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.59 by $0.08. Edwards Lifesciences had a net margin of 23.25% and a return on equity of 14.70%. The company had revenue of $1.55 billion during the quarter, compared to analysts’ expectations of $1.49 billion. During the same period last year, the company posted $0.67 earnings per share. The firm’s quarterly revenue was up 14.7% compared to the same quarter last year. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS and its Q4 2025 guidance at 0.580-0.640 EPS. Equities research analysts anticipate that Edwards Lifesciences will post 2.45 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Piper Sandler restated an “overweight” rating and issued a $95.00 price target (up previously from $90.00) on shares of Edwards Lifesciences in a research report on Friday, October 31st. Oppenheimer downgraded shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research note on Wednesday, October 8th. Wells Fargo & Company restated an “overweight” rating and set a $96.00 target price on shares of Edwards Lifesciences in a research report on Friday. Citigroup lifted their target price on shares of Edwards Lifesciences from $95.00 to $96.00 and gave the stock a “buy” rating in a research note on Friday, October 31st. Finally, Wall Street Zen lowered Edwards Lifesciences from a “strong-buy” rating to a “buy” rating in a research note on Monday, September 29th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $91.87.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Daniel J. Lippis sold 1,020 shares of Edwards Lifesciences stock in a transaction on Monday, November 10th. The shares were sold at an average price of $82.55, for a total value of $84,201.00. Following the transaction, the vice president owned 22,002 shares in the company, valued at $1,816,265.10. This trade represents a 4.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Scott B. Ullem sold 13,000 shares of the business’s stock in a transaction on Monday, November 10th. The shares were sold at an average price of $83.08, for a total transaction of $1,080,040.00. Following the sale, the chief financial officer directly owned 39,898 shares of the company’s stock, valued at $3,314,725.84. This represents a 24.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 1.29% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in EW. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Edwards Lifesciences by 278.3% in the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock worth $434,318,000 after purchasing an additional 4,108,270 shares during the period. Invesco Ltd. increased its position in Edwards Lifesciences by 9.0% during the 3rd quarter. Invesco Ltd. now owns 3,570,216 shares of the medical research company’s stock worth $277,656,000 after purchasing an additional 294,175 shares in the last quarter. Viking Global Investors LP purchased a new position in Edwards Lifesciences in the third quarter valued at approximately $238,688,000. AQR Capital Management LLC lifted its position in Edwards Lifesciences by 114.5% during the third quarter. AQR Capital Management LLC now owns 2,081,346 shares of the medical research company’s stock valued at $161,055,000 after buying an additional 1,111,139 shares in the last quarter. Finally, Man Group plc lifted its position in Edwards Lifesciences by 19.0% during the third quarter. Man Group plc now owns 1,967,433 shares of the medical research company’s stock valued at $153,007,000 after buying an additional 313,494 shares in the last quarter. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.